TMRW’s technology provides the world’s first and only fully automated specimen management platform (CryoRobot) that identifies, tracks, and manages frozen eggs and embryos – central to almost every IVF journey.  Vios Fertility Institute’s Chicago lab was the first in the world to adopt this revolutionary technology in early 2021.  

Bioretec’s target is to receive the CE mark and to introduce the bioresorbable magnesium alloy trauma screw into the markets in the European Union during 2022.

Omeros received approximately $126 million in cash at closing. In addition, Omeros retains and is entitled to collect the full amount of its accounts receivable outstanding as of today’s closing.